In 2021, cancer diagnostics achieved a long-discussed “Holy Grail” milestone with the commercial launch of a liquid biopsy blood test for early cancer detection. While questions surround the adoption of the test, many are already looking to next-generation advances that can build upon
this moment. In this panel, leaders from companies pursuing different paths in early cancer detection discuss their vision for future liquid biopsies, the technological advances making them possible, and the promise for patients. Panelists will also provide insight on the benefits of focusing cancer-detection efforts on specific high-risk patient populations or how the technology can scale across all cancers. In addition, the companies will discuss the influence these new technologies and early detection can have on cancer drug development, including how they plan to utilize the advances for companion diagnostics in precision oncology.